Gaithersburg, MD: Aspen Publishers, Inc., 1996 Found it
doi: 10.2174/1568026615666150813142215 268 SukT
SURMOUNT and SURMOUNT-OSA: what the tirzepatide trials showed The evidence behind tirzepatide sits within the broader compound class GLP-1 receptor agonists such as semaglutide, liraglutide and dulaglutide, and the GIP/GLP-1 dual agonist tirzepatide itself
It also lowers the risk of major cardiovascular events such as stroke, heart attack, or death in adults with type 2 diabetes who also have heart disease, and lowers the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes who also have chronic kidney disease
Another big reason is that it helps you avoid common injection site reactions[1] , which may include: Redness or warmth Swelling or slight bruising Itching or tenderness Small lumps or bumps under the skin Most of these are mild and temporary, but they can become uncomfortable if you keep using the same spot or inject incorrectly
Long-term benefits (8-12 weeks and beyond) could include cardiovascular improvements, reduced scarring after injuries, and better gastrointestinal health, among other things
